Rui Ma

机构：Xinjiang Medical University, Beijing University of Chinese Medicine, Hainan University, Gansu University of Traditional Chinese Medicine, Universitas Prima Indonesia, Henan University of Engineering, Gansu Provincial Maternal and Child Health Hospital, First Affiliated Hospital of Henan University, Xijing Hospital, Liaoning Cancer Hospital & Institute, Chengdu University of Traditional Chinese Medicine, China Medical University, Xinjiang University, Air Force Medical University · ORCID：0000-0001-9317-9377

发表论文 97 篇 · 总被引 2045 次 · h-index 19

代表论文

• Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 61)
• Mechanisms and treatment of atherosclerosis: focus on macrophages (2024 · Frontiers in Immunology · 被引 33)
• Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as First-Line Treatment for Extensive-Stage SCLC: Results of a Phase 1b Clinical Trial (2024 · Journal of Thoracic Oncology · 被引 19)
• Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial (2025 · The Lancet Oncology · 被引 17)
• Discovery of novel rigid STING PROTAC degraders as potential therapeutics for acute kidney injury (2025 · European Journal of Medicinal Chemistry · 被引 11)
• Discovery of RigidLinker-Based IRAK4 PROTACs withImproved Metabolic Stability for the Treatment of Inflammatory Diseases (2025 · Journal of Medicinal Chemistry · 被引 10)